[A case of gemcitabine-based chemo-radiation therapy for unresectable pancreatic cancer with liver metastases].
We report a case of advanced unresectable pancreatic cancer with multiple liver metastases (cT4N x M1, stage IVb). The patient is a 68-year-old man. Serum DUPAN-2 was 15,800 U/mL. Abdominal CT scan revealed the body and tail of pancreatic cancer and multiple liver metastases. Chemo-radiation therapy (CRT) with GEM 1000 mg/body was given once a week on days 1, 8 and 15 for 3 weeks. The radiotherapy dose was 45 Gy (1.5 Gy x 2/day, 15 days). Hematological side effect such as anemia (grade 3) and thrombopenia (grade 2) appeared, but could be well controlled. Abdominal CT scan revealed no change in size, but serum DUPAN-2 decreased up to 4590 U/mL. After CRT, the patient was treated thereafter by the combination chemotherapy with GEM and S-1. After 7 months, CT scan revealed no change in tumor size.
Yamashita
Shinya
S
Dept. of Surgery, Nishinomiya Municipal Center Hospital.
Sakon
Masato
M
Hiura
Yuichiro
Y
Nakano
Katsutoshi
K
Higaki
Naozumi
N
Murakami
Masakazu
M
Hayashida
Hirohito
H
Kan
Kazuomi
K
Ichihara
Takao
T
D000368:Aged; D000951:Antigens, Neoplasm / Q000097:blood; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000097:blood; D003131:Combined Modality Therapy; D003841:Deoxycytidine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D008113:Liver Neoplasms / Q000097:blood / Q000188:drug therapy* / Q000532:radiotherapy* / Q000556:secondary; D008297:Male; D010190:Pancreatic Neoplasms / Q000097:blood / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy*; D013997:Time Factors; D014057:Tomography, X-Ray Computed; D000093542:Gemcitabine
D000951:Antigens, Neoplasm; D014408:Biomarkers, Tumor; C042317:DU-PAN-2 antigen, human; D003841:Deoxycytidine; D000093542:Gemcitabine